Insmed Incorporated
INSM
Jodie situation report
Insmed Incorporated's current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 7 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.
- INSM's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if INSM's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind INSM
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
AZNAstraZeneca PLCpartnerMay 7, 2026 ▾
“Brensocatib is a small molecule, reversible inhibitor of DPP1, which we licensed from AstraZeneca in October 2016.”
Depended on by
RGNXREGENXBIO Inc.competitorMar 5, 2026 ▾
“There are three principal competitive gene therapy products in clinical development from Solid Biosciences (SGT-003), Genethon (GNT0004), and Insmed (INS1201).”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
INSM is currently a Participant in the organic co-movement group No Coherent Theme. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for INSM; it is not active in the latest market snapshot.